VCBeat Health
Contact Us
Home
China Healthcare Select
Insights
MNC China Lens
Vertical Industries
Services
About VCBeat
Why VCBeat
Log In
Home
Junshi Biosciences: Toripalimab Phase III NEOTORCH Study Meets All Primary Endpoints in Resectable Stage II-III NSCLC
Junshi Biosciences: Toripalimab Phase III NEOTORCH Study Meets All Primary Endpoints in Resectable Stage II-III NSCLC
May 26, 2026 18:19 CST Updated 19:18
Share:
Junshi Biosciences
Innovative Drug Developer